Fate Therapeutics, Inc. (FATE) Receives Average Rating of “Buy” from Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $7.00.
A number of research firms have issued reports on FATE. Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Tuesday, May 16th. ValuEngine lowered shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Creative Planning raised its position in Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6,000 shares during the last quarter. KCG Holdings Inc. raised its position in Fate Therapeutics by 7.8% in the first quarter. KCG Holdings Inc. now owns 24,480 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,764 shares during the last quarter. Rhumbline Advisers purchased a new position in Fate Therapeutics during the second quarter worth about $133,000. Driehaus Capital Management LLC purchased a new position in Fate Therapeutics during the first quarter worth about $145,000. Finally, Hillsdale Investment Management Inc. purchased a new position in Fate Therapeutics during the first quarter worth about $160,000. 60.74% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/07/fate-therapeutics-inc-fate-receives-average-rating-of-buy-from-brokerages.html.
Fate Therapeutics (FATE) traded down 4.76% on Monday, reaching $2.80. 112,488 shares of the company traded hands. Fate Therapeutics has a 12 month low of $1.80 and a 12 month high of $5.68. The company has a 50-day moving average price of $3.11 and a 200-day moving average price of $3.70. The company’s market capitalization is $115.92 million.
Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.03. The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.04 million. Fate Therapeutics had a negative net margin of 857.34% and a negative return on equity of 75.93%. Equities research analysts expect that Fate Therapeutics will post ($1.00) EPS for the current year.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.